ARBs Associated with Reduced Dementia and Alzheimer Disease Risk
Angiotensin-receptor blockers (ARBs) are associated with reduced risk for dementia and Alzheimer disease, according to a BMJ study.
Researchers analyzed Veterans Affairs records of 800,000 mostly male patients aged 65 and older with cardiovascular disease. Over the 4-year observation period, patients taking ARBs were less likely to develop dementia or Alzheimer disease, to be admitted to a nursing home, or to die than were patients taking the ACE-inhibitor lisinopril or other cardiovascular drugs, such as beta-blockers or calcium channel antagonists. Patients taking both ARBs and ACE-inhibitors saw a further risk reduction.
The authors suggest that ARBs may protect against cognitive decline by limiting neuronal damage linked to stroke and vascular problems.
Angiotensin-receptor blockers (ARBs) are associated with reduced risk for dementia and Alzheimer disease, according to a BMJ study.
Researchers analyzed Veterans Affairs records of 800,000 mostly male patients aged 65 and older with cardiovascular disease. Over the 4-year observation period, patients taking ARBs were less likely to develop dementia or Alzheimer disease, to be admitted to a nursing home, or to die than were patients taking the ACE-inhibitor lisinopril or other cardiovascular drugs, such as beta-blockers or calcium channel antagonists. Patients taking both ARBs and ACE-inhibitors saw a further risk reduction.
The authors suggest that ARBs may protect against cognitive decline by limiting neuronal damage linked to stroke and vascular problems.